Phibro Animal Health Analyst Ratings
Phibro Animal Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 47.16% | Roth MKM | → $21 | Reiterates | Buy → Buy |
| 08/31/2023 | 19.13% | Morgan Stanley | $18 → $17 | Maintains | Equal-Weight |
| 08/29/2023 | 47.16% | Roth MKM | → $21 | Reiterates | Buy → Buy |
| 07/27/2023 | 26.14% | Morgan Stanley | $18 → $18 | Reiterates | Equal-Weight → Equal-Weight |
| 05/04/2023 | 26.14% | Morgan Stanley | $19 → $18 | Maintains | Equal-Weight |
| 02/09/2023 | 33.15% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
| 12/21/2022 | 26.14% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 11/10/2022 | 40.15% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight |
| 09/16/2022 | 19.13% | Barclays | $22 → $17 | Maintains | Underweight |
| 08/26/2022 | 47.16% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight |
| 07/25/2022 | 54.17% | Barclays | → $22 | Downgrades | Equal-Weight → Underweight |
| 01/10/2022 | 61.18% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
| 11/18/2021 | 61.18% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 07/07/2021 | 61.18% | Barclays | → $23 | Downgrades | Equal-Weight → Underweight |
| 05/13/2021 | 54.17% | Morgan Stanley | $19 → $22 | Maintains | Underweight |
| 05/08/2020 | 61.18% | Credit Suisse | $25 → $23 | Maintains | Neutral |
| 02/06/2020 | — | Gabelli & Co. | Downgrades | Buy → Hold | |
| 01/28/2020 | 61.18% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
| 09/05/2019 | 47.16% | Morgan Stanley | $30 → $21 | Upgrades | Underweight → Equal-Weight |
| 08/29/2019 | 26.14% | B of A Securities | $29 → $18 | Reiterates | → Underperform |
| 08/29/2019 | 26.14% | Barclays | $25 → $18 | Maintains | Underweight |
| 08/28/2019 | 75.19% | Credit Suisse | $31 → $25 | Reiterates | → Neutral |
| 06/11/2019 | 75.19% | Barclays | → $25 | Initiates Coverage On | → Underweight |
| 05/09/2019 | — | Gabelli & Co. | Upgrades | Hold → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/01/2023 | 47.16% | 罗斯MKM | →$21 | 重申 | 购买→购买 |
| 2023年08月31日 | 19.13% | 摩根士丹利 | $18→$17 | 维护 | 等重 |
| 2023年08月29日 | 47.16% | 罗斯MKM | →$21 | 重申 | 购买→购买 |
| 07/27/2023 | 26.14% | 摩根士丹利 | $18→$18 | 重申 | 等重→等重 |
| 05/04/2023 | 26.14% | 摩根士丹利 | $19→$18 | 维护 | 等重 |
| 02/09/2023 | 33.15% | 摩根士丹利 | $20→$19 | 维护 | 等重 |
| 2022年12月21日 | 26.14% | 罗斯资本 | →$18 | 开始承保 | →购买 |
| 2022年11月10日 | 40.15% | 摩根士丹利 | $21→$20 | 维护 | 等重 |
| 09/16/2022 | 19.13% | 巴克莱 | $22→$17 | 维护 | 体重不足 |
| 2022年08月26日 | 47.16% | 摩根士丹利 | $23→$21 | 维护 | 等重 |
| 07/25/2022 | 54.17% | 巴克莱 | →$22 | 评级下调 | 等重→减码 |
| 2022年1月10日 | 61.18% | 巴克莱 | →$23 | 升级 | 重量不足的→等重 |
| 2021年11月18日 | 61.18% | 摩根士丹利 | →$23 | 开始承保 | →等重 |
| 07/07/2021 | 61.18% | 巴克莱 | →$23 | 评级下调 | 等重→减码 |
| 2021/05/13 | 54.17% | 摩根士丹利 | $19→$22 | 维护 | 体重不足 |
| 05/08/2020 | 61.18% | 瑞士信贷 | $25→$23 | 维护 | 中性 |
| 02/06/2020 | - | 加贝利公司 | 评级下调 | 购买→Hold | |
| 1/28/2020 | 61.18% | 巴克莱 | →$23 | 升级 | 重量不足的→等重 |
| 2019年05月09日 | 47.16% | 摩根士丹利 | $30→$21 | 升级 | 重量不足的→等重 |
| 2019年08月29日 | 26.14% | B of A证券 | $29→$18 | 重申 | →表现不佳 |
| 2019年08月29日 | 26.14% | 巴克莱 | $25→$18 | 维护 | 体重不足 |
| 2019年08月28日 | 75.19% | 瑞士信贷 | $31→$25 | 重申 | →中性 |
| 2019年6月11日 | 75.19% | 巴克莱 | →$25 | 开始承保 | →减持 |
| 2019年05月09日 | - | 加贝利公司 | 升级 | 持有→购买 |
What is the target price for Phibro Animal Health (PAHC)?
Phibro Animal Health(PAHC)的目标价格是多少？
The latest price target for Phibro Animal Health (NASDAQ: PAHC) was reported by Roth MKM on September 1, 2023. The analyst firm set a price target for $21.00 expecting PAHC to rise to within 12 months (a possible 47.16% upside). 9 analyst firms have reported ratings in the last year.
罗斯MKM于2023年9月1日报道了菲布罗动物健康公司(纳斯达克：PAHC)的最新目标价。这家分析公司将目标价定为21.00美元，预计PAHC将在12个月内上涨至47.16%(可能上涨47.16%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Phibro Animal Health (PAHC)?
菲布罗动物健康(PAHC)的最新分析师评级是多少？
The latest analyst rating for Phibro Animal Health (NASDAQ: PAHC) was provided by Roth MKM, and Phibro Animal Health reiterated their buy rating.
菲布罗动物健康公司(纳斯达克代码：PAHC)的最新分析师评级由Roth MKM提供，菲布罗动物健康公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Phibro Animal Health (PAHC)?
菲布罗动物健康(PAHC)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phibro Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phibro Animal Health was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与菲布罗动物健康公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。菲布罗动物健康的上一次评级是在2023年9月1日提交的，所以你应该预计下一次评级将在2024年9月1日左右的某个时候公布。
Is the Analyst Rating Phibro Animal Health (PAHC) correct?
分析师对Phibro Animal Health(PAHC)的评级正确吗？
While ratings are subjective and will change, the latest Phibro Animal Health (PAHC) rating was a reiterated with a price target of $0.00 to $21.00. The current price Phibro Animal Health (PAHC) is trading at is $14.27, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但菲布罗动物健康(PAHC)的最新评级被重申，目标价在0.00美元至21.00美元之间。Phibro Animal Health(PAHC)目前的交易价格为14.27美元，在分析师的预测范围内。